ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Variants of SARS-CoV-2 Causing COVID-19 in Africa

Conditions: COVID-19

Interventions: Diagnostic Test: RT PCR

First Posted Date: 2022-04-05

Last Posted Date: 2022-05-27

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 12600

Registration Number: NCT05311891

Locations: 🇨🇬
Laboratoire National de Santé Publique Brazzaville, Brazzaville, Congo
🇲🇱
SEREFO, Bamako, Mali
🇨🇮
CIRBA, Abidjan, Côte D'Ivoire

and more 3 locations

Transmission of Covid-19 During Clubbing Events in Closed Places

Not Applicable

Completed

Conditions: Healthy Participant

Interventions: Other: Club event

First Posted Date: 2022-04-05

Last Posted Date: 2022-04-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 1216

Registration Number: NCT05311865

Locations: 🇫🇷
ANRS, Paris, France

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

Phase 2

Recruiting

Conditions: HIV/AIDS and Infections

Interventions: Drug: Recombinant human monoclonal antibody (bNAbs)
Drug: Placebo

First Posted Date: 2022-03-29

Last Posted Date: 2024-12-27

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 69

Registration Number: NCT05300035

Locations: 🇫🇷
Hôpial Avicenne - SMIT, Bobigny, France
🇫🇷
Hôpital Antoine Béclère, Clamart, France
🇫🇷
Hôpital Beaujon - Service de médecine interne, Clichy, France

and more 14 locations

Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial

Terminated

Conditions: HIV Seropositivity

Interventions: Other: Self-administered questionnaires
Other: Semi-directive individual interviews

First Posted Date: 2022-03-15

Last Posted Date: 2023-05-15

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 6

Registration Number: NCT05280392

Locations: 🇨🇭
CHUV, Lausanne, Switzerland

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

Phase 1

Recruiting

Conditions: HIV-1-infection, Subtype b

Interventions: Drug: Decitabine cycle 1
Drug: Romidepsin cycle 1
Drug: Decitabine cycle 2
Drug: Romidepsin cycle 2
Drug: Decitabine cycle 3
Drug: Romidepsin cycle 3
Drug: Decitabine cycle 4
Drug: Romidepsin cycle 4

First Posted Date: 2022-02-08

Last Posted Date: 2024-10-30

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 15

Registration Number: NCT05230368

Locations: 🇧🇪
CHU Saint-Pierre, Bruxelles, Belgium

A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing bictégravir, Emtricitabine and ténofovir alafénamide

Not Applicable

Not yet recruiting

Conditions: HIV-1-infection

Interventions: Other: Biopsies and bloood samplings

First Posted Date: 2022-02-03

Last Posted Date: 2024-08-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 34

Registration Number: NCT05222945

Locations: 🇫🇷
Necker Hospital, Paris, France
🇫🇷
Antoine-Beclere Hospita, Clamart, France
🇫🇷
Hotel Dieu Hospital, Paris, France

and more 3 locations

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

Recruiting

Conditions: Immunocompromised Host
COVID-19

First Posted Date: 2022-01-31

Last Posted Date: 2023-02-01

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 200

Registration Number: NCT05216588

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France

Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers

Phase 2

Conditions: Ebola Virus Disease

Interventions: Biological: Ervebo
Drug: Inmazeb

First Posted Date: 2022-01-21

Last Posted Date: 2022-01-21

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 135

Registration Number: NCT05202288

Locations: 🇬🇳
Research center of Landreah, Conakry, Guinea

ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation

Phase 2

Conditions: Hepatitis B, Chronic

Interventions: Drug: administration of SLGN in arm C
Drug: Discontinuation of NUC treatment in arms B and C

First Posted Date: 2021-09-16

Last Posted Date: 2022-03-14

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT05045261

Locations: 🇫🇷
Hepato-gastroenterology department, Hôpital Saint-Joseph, Marseille, France
🇮🇹
Gastroenterology and Hepatology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
🇫🇷
Hepatology Department, Hospices Civils de Lyon, Lyon, France

and more 5 locations

Prevention of Mental Health Problems Among Persons Without Personal Housing in the Context of the COVID-19 Epidemic

Not Applicable

Conditions: Quality of Life
Psychosocial Intervention
Psychological Distress

Interventions: Behavioral: Psychological First Aid (PFA)
Behavioral: Care as Usual (CAU)
Behavioral: Doing What Matters in Times of Stress (DWM)
Behavioral: Problem Management Plus (PM+)

First Posted Date: 2021-09-02

Last Posted Date: 2022-07-25

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 210

Registration Number: NCT05033210

Locations: 🇫🇷
CAPSYS, Paris, Île De France, France
🇫🇷
Normandy Psychotrauma Center, Caen, Normandie, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy